What is GLP-1 and how does it cause weight loss?
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your brain you're full, slows digestion and steadies blood sugar. In many people with obesity this signal is too weak. GLP-1 medications amplify it — quieting the constant hunger or “food noise” that drives overeating, so you naturally eat less.
Real resultsWhich GLP-1 medications are available in India?
The two leading options are tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy, Rybelsus). Mounjaro launched in India in March 2025 and works on two hormone receptors. Semaglutide became much cheaper after its patent expired in March 2026, with 40+ generics now available. A doctor chooses between them based on your clinical picture.
How much does GLP-1 weight loss cost in India?
Cost depends on the medicine and dose. Generic semaglutide runs roughly ₹1,300–₹4,200/month in 2026, while Mounjaro ranges from about ₹13,125/month (2.5 mg) to ₹25,781/month (15 mg). A complete MetaFit care program — consultation, medication where prescribed, diagnostics, AI coaching and a care team — is offered as a transparent monthly subscription.
Who is eligible for GLP-1 medication in India?
GLP-1 medication is generally considered for adults with a BMI of 30+, or 27+ with a weight-related condition such as type 2 diabetes, PCOS, fatty liver or hypertension. Because Asian Indians develop metabolic risk at lower BMIs, the threshold can be lower. A qualified clinician confirms eligibility after reviewing your health.
Why does muscle preservation matter on GLP-1?
Without resistance training and enough protein, up to 40% of the weight lost on GLP-1 can come from muscle. That harms metabolism and makes regain easier. MetaFit pairs medication with protein-optimised nutrition and strength workouts so you lose fat while protecting muscle — a core difference from prescription-only telehealth.
How does a MetaFit GLP-1 program work?
You start with a short online health review. A qualified clinician evaluates your metabolic profile and, if appropriate, prescribes GLP-1 medication delivered to your door. From there you get a 24/7 AI health coach, Indian-diet nutrition planning, strength guidance and a dedicated care team — built around how India actually eats.
Mounjaro vs semaglutide in India (2026 at a glance)
| Tirzepatide (Mounjaro) | Semaglutide (Ozempic/Wegovy) | |
|---|---|---|
| Receptors | GIP + GLP-1 (dual) | GLP-1 (single) |
| Avg. weight loss (trials) | Up to ~20–22% | ~15% |
| Indicative price / month | ₹13,125 – ₹25,781 | ₹1,300 – ₹4,200 (generic) |
| Generics in India | No (patent to ~2036) | Yes (since Mar 2026) |
| Schedule | Once weekly | Weekly (or daily tablet) |
Indicative 2026 figures; a clinician decides which medication suits you.
GLP-1 is the biggest advance in obesity care in a generation — but in India it works best when it's localised: dosed carefully, built around our food, and combined with protein and strength training rather than handed over as a prescription alone.